This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perez-Stable, C. M. Articles by Roos, B. A. Search for Related Content PubMed PubMed Citation Articles by Perez-Stable, C. M. Articles by Roos, B. A.

The G/T-15 Transgenic Mouse Model of Androgen-independent Prostate Cancer: Target Cells of Carcinogenesis and the Effect of the Vitamin D Analogue EB 1089¹

Geriatric Research, Education, and Clinical Center and Research Service, Veterans Affairs Medical Center, Miami, Florida 33125 [C. M. P-S., A. F., G. A. H., B. A. R.]; Departments of Medicine [C. M. P-S., G. A. H., B. A. R.], Biochemistry and Molecular Biology [G. A. H.], and Neurology [B. A. R.] and Sylvester Comprehensive Cancer Center [C. M. P-S., G. A. H., B. A. R.], University of Miami School of Medicine, Miami Florida 33101; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157 [G. G. S.]; Texas Children’s Hospital, Houston, Texas 77030 (M. F.); and Leo Pharmaceuticals, Ballerup, Denmark [L. B.]

Transgenic mouse models of prostate cancer provide unique opportunitiesto understand the molecular events in prostate carcinogenesis and for the preclinical testing of new therapies. We studied the GT-15 transgenic mouse line, which contains the human fetal globin promoter linked to SV40 T antigen (Tag) and which develops androgen-independent prostate cancer. Using the immunohistochemistry of normal mouse prostates before tumor formation, we showed that the target cells of carcinogenesis in GT-15 mice are located in the basal epithelial layer. We tested the efficacy of the 1,25(OH)₂D₃ analogue, EB 1089, to chemoprevent prostate cancer in these transgenic mice. Compared with treatment with placebo, treatment with EB 1089 at three different time points before the onset of prostate tumors in mice did not prevent or delay tumor onset. However, EB 1089 significantly inhibited prostate tumor growth. At the highest dose, EB1089 inhibited prostate tumor growth by 60% (P = 0.0003) and the growth in the number of metastases, although this dose also caused significant hypercalcemia and weight loss. We conducted several in vitro experiments to explore why EB 1089 did not prevent the occurrence of the primary tumors. EB1089 significantly inhibited the growth of a Tag-expressing human prostate epithelial cell line, BPH-1, and an androgen-insensitive subline of LNCaP cells [which was not inhibited by 1,25(OH)₂D₃]. Thus, neither Tag expression nor androgen insensitivity explain the absence of chemopreventive effect. Conversely, neither 1,25(OH)₂D₃ nor EB 1089 inhibited the growth of the normal rat prostate basal epithelial cell line NRP-152. It is likely that EB 1089 was not effective in delaying the growth of the primary tumor in GT-15 transgenic mice because the target cells of carcinogenesis in these mice are located in the basal epithelial layer. We conclude that GT-15 transgenic mice are a useful model for testing vitamin D-based therapies in androgen-insensitive prostate cancer but are not suitable for studies of vitamin D-based chemoprevention. The superiority of EB 1089 over 1,25(OH)₂D₃ in the growth suppression of androgen-insensitive prostate cancer cells supports the use of EB 1089 in androgen-insensitive prostate cancer.

This article has been cited by other articles:

				T. Reiner, A. de las Pozas, R. Parrondo, and C. Perez-Stable Progression of Prostate Cancer from a Subset of p63-Positive Basal Epithelial Cells in FG/Tag Transgenic Mice Mol. Cancer Res., November 1, 2007; 5(11): 1171 - 1179. [Abstract] [Full Text] [PDF]

				L. A. Gomez, A. de las Pozas, and C. Perez-Stable Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226. [Abstract] [Full Text] [PDF]

				R. Hill, Y. Song, R. D. Cardiff, and T. Van Dyke Heterogeneous Tumor Evolution Initiated by Loss of pRb Function in a Preclinical Prostate Cancer Model Cancer Res., November 15, 2005; 65(22): 10243 - 10254. [Abstract] [Full Text] [PDF]